HopeStage
Back to all studies
CompletedNCT01267188

Three Doses of NBI-98854 for Tardive Dyskinesia

About this titleRead the official source — NCT01267188

This study evaluated the safety and effectiveness of NBI-98854 for people with schizophrenia.

Medication studyAges 18–65Canada
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of NBI-98854 for people with schizophrenia.

Who was this study for?

Listed age limits: 18 years to 65 years.

Listed locations
TorontoSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2011
Recruitment status
Completed
Enrollment listed in the registry
10
Sponsor
Neurocrine Biosciences
Sponsor type
Biotech company
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT01267188
Official title
Show the full official title

A Phase 2, Open-Label, Dose Titration Study to Evaluate the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of NBI-98854 for people with schizophrenia.

Who is behind this study?

The study sponsor is Neurocrine Biosciences, a biotech company.

Did this study involve medication?

Yes. The study involved medication, including NBI-98854.

Who was this study for?

Listed age limits: 18 years to 65 years.

Want to explore more studies?

Explore studies